The first subjects have been dosed in two separate Phase I clinical trials evaluating the safety, tolerability, and pharmacokinetics of Sionna Therapeutics’ SION-719 and SION-451 in healthy volunteers.

SION-719 and SION-451 are product candidates from the company’s series of highly potent nucleotide-binding domain 1 (NBD1) stabilisers for cystic fibrosis (CF). The trials are being conducted in Australia under the Clinical Trial Notification (CTN) process.

“We are pleased with the company’s strong execution and the progress these first-in-class programmes have made in entering the clinic,” said Mike Cloonan, President and Chief Executive Officer of Sionna. “We have a novel ability to target NBD1, which we believe could be the key to raising the efficacy bar and unlocking improved clinical benefits for CF patients. We expect that the data from these single and multiple ascending dose trials will inform our decision about a lead NBD1 stabiliser to bring forward into the next stages of clinical development.”

CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which codes for an epithelial ion channel that is essential for producing healthy, freely flowing mucus in the airways, digestive system, and other organs.

The most common mutation in CFTR, F508del, causes NBD1 to unfold at body temperature and severely impairs CFTR function.

Sionna has presented preclinical data, including data from the clinically predictive human bronchial epithelial cell (CFHBE) model, showing that SION-719 and SION-451, when combined with complementary modulators, significantly improve in vitro CFTR protein activity and demonstrate the potential to achieve superior clinical outcomes.

The company is also developing complementary modulators with the goal of advancing differentiated combination therapies for CF.

Diana Spencer, Senior Digital Content Editor, DDW